Top Markets
#1 Official Trump Official Trump +51.60%
#2 Movement Movement +32.33%
#3 Mubarak Mubarak +26.27%
#4 Pearl Pearl +24.49%
#5 Zama Zama +24.44%
#6 Melania Meme Melania Meme +22.38%
#7 EXOD EXOD +18.93%
#8 Wrapped POL Wrapped POL +18.74%
#9 POL (ex-MATIC) POL (ex-MATIC) +18.66%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +16.92%
Coin of the day
Official Trump Official Trump
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Citius Oncology, Inc. Citius Oncology, Inc.

Citius Oncology, Inc.

CTOR
Pozycja w akcjach #23802
Citius Oncology, Inc. concentrates on advancing innovative, targeted... Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Cena akcji
$0.7426
Ostatnia synchronizacja: 2026-08-21
Kapitalizacja rynkowa
$69.05M
Zmiana (1 dzień)
-2.17%
Zmiana (1 rok)
-57.57%
Kraj
US
Handel Citius Oncology, Inc. (CTOR)

Kategoria

Healthcare
Historia stopy dywidendy dla Citius Oncology, Inc. (CTOR)
Stopa dywidendy (TTM) dla Citius Oncology, Inc. (symbol akcji: CTOR) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Citius Oncology, Inc. (CTOR) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji
Firma Stopa dywidendy Kraj
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
0.57%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
2.01%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
2.74%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
2.69%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
2.47%
US